Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Brian Jonas
- Target Recruit Count
- 20
- Registration Number
- NCT04905810
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸UCSF-Fresno, Clovis, California, United States
Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML
- Conditions
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 95
- Registration Number
- NCT04905407
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇫🇷Hôpital l'Archet- CHU de Nice, Nice, France
🇺🇸City of Hope, Duarte, California, United States
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04898894
- Locations
- 🇺🇸
Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Rady Children's Hospital-San Diego, San Diego, California, United States
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 75
- Registration Number
- NCT04895436
- Locations
- 🇮🇹
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 229504, Torino, Piemonte, Italy
🇬🇧Blackpool Victoria Hospital /ID# 267280, Blackpool, Lancashire, United Kingdom
🇺🇸Des Moines Oncology Research Association /ID# 232606, Des Moines, Iowa, United States
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT04887857
- Locations
- 🇺🇸
Local Institution - 105, Boston, Massachusetts, United States
🇺🇸Local Institution - 102, Cleveland, Ohio, United States
🇦🇺Local Institution - 201, Melbourne, Australia
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04874194
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04872790
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Avo in R/R and Previously Untreated MCL
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Austin I Kim
- Target Recruit Count
- 53
- Registration Number
- NCT04855695
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyDrug: DexamethasoneDrug: Ixazomib CitrateProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Transabdominal UltrasoundDrug: VenetoclaxProcedure: X-Ray Imaging
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT04847453
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Safe Accelerated Venetoclax Escalation in CLL
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04843904
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.